Evan L Barrios, Monty B Mazer, Patrick W McGonagill, Christian B Bergmann, Michael D Goodman, Robert W Gould, Mahil Rao, Valerie E Polcz, Ruth Davis, Drew Del Toro, Marvin Dirain, Alexandra Dram, Lucas Hale, Mohammad Heidarian, Caleb Y Kim, Tamara A Kucaba, Jennifer P Lanz, Ashley McCray, Alexandra Meszaros, Sydney M Miles, Candace Nelson, Ivanna Rocha, Elvia E Silva, Ricardo Ungaro, Andrew Walton, Julie Xu, Leilani Zeumer-Spataro, Anne M Drewry, Muxuan Liang, Letita E Bible, Tyler J Loftus, Isaiah R Turnbull, Philip A Efron, Kenneth E Remy, Scott C Brakenridge, Vladimir P Badovinac, Thomas S Griffith, Lyle L Moldawer, Richard S Hotchkiss, Charles C Caldwell
BACKGROUND: Sepsis remains a major clinical challenge for which successful treatment requires greater precision in identifying patients at increased risk of adverse outcomes requiring different therapeutic approaches. Predicting clinical outcomes and immunological endotyping of septic patients has generally relied on using blood protein or mRNA biomarkers, or static cell phenotyping. Here, we sought to determine whether functional immune responsiveness would yield improved precision. METHODS: An ex vivo whole blood enzyme-linked immunosorbent (ELISpot) assay for cellular production of interferon-γ (IFN-γ) was evaluated in 107 septic and 68 non-septic patients from five academic health centers using blood samples collected on days 1, 4 and 7 following ICU admission...
December 15, 2023: JCI Insight